B+
Bull case
20%
Probability
Target price
$1.20
+92.6% vs current
CNTX
Context TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$0.65
+4.4% vs current
B-
Bear case
30%
Probability
Target price
$0.30
-51.8% vs current
AI sentiment snapshot
Latest data as of 2026-07-18
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+54.9
Score
AI commentary
Primary-source evidence is strong for a low-coverage biotech because the company provided detailed June CTIM-76 interim results and SEC filings provide financing context. Sentiment is fragile after the reported post-data selloff. Social, options, and validated analyst-revision data are unavailable, so the report remains a cautious monitoring view rather than a confirmed sentiment reversal.
RankAlpha Sentiment Codex - 2026-07-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30eventCT-95 Phase 1a interim dataHigh impact
The prior baseline identifies September 2026 interim data for CT-95 as a pipeline-breadth checkpoint. A credible readout could reduce single-asset dependence; delay or weak activity would reinforce concentration risk [#SEC-10Q-2026-05-06].
2026-10-16eventCTIM-76 Q3W development updateHigh impact
The company reported a 29% confirmed response rate, 57% disease-control rate, limited Grade 1 CRS, and pharmacokinetic support for exploring every-three-week dosing in the second half of 2026. Confirmation of activity, safety, and durability as development broadens could support a rerating [#PR-EARNINGS-2026-06-15].
2026-10-16catalystPost-data validation and volatilityHigh impact
The June CTIM-76 update showed encouraging but early efficacy and safety data, while recent market coverage described an exceptionally sharp selloff after the ovarian-cancer data. Near-term trading remains sensitive to durability, sample-size, and follow-through concerns.
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology